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Abstract: Herpes simplex virus type 1 (HSV-1) amplicons can accommodate foreign DNA of any size up to 150 kbp and, 
therefore, allow extensive combinations of genetic elements. Genomic sequences as well as cDNA, large transcriptional 
regulatory sequences for cell type-specific expression, multiple transgenes, and genetic elements from other viruses to 
create hybrid vectors may be inserted in a modular fashion. Hybrid amplicons use genetic elements from HSV-1 that 
allow replication and packaging of the vector DNA into HSV-1 virions, and genetic elements from other viruses that 
either direct integration of transgene sequences into the host genome or allow episomal maintenance of the vector. Thus, 
the advantages of the HSV-1 amplicon system, including large transgene capacity, broad host range, strong nuclear 
localization, and availability of helper virus-free packaging systems are retained and combined with those of heterologous 
viral elements that confer genetic stability to the vector DNA. Adeno-associated virus (AAV) has the unique capability of 
integrating its genome into a specific site, designated AAVS1, on human chromosome 19. The AAV rep gene and the 
inverted terminal repeats (ITRs) that flank the AAV genome are sufficient for this process. HSV-1 amplicons have thus 
been designed that contain the rep gene and a transgene cassette flanked by AAV ITRs. These HSV/AAV hybrid vectors 
direct site-specific integration of transgene sequences into AAVS1 and support long-term transgene expression. 
Keywords: HSV-1 amplicon vectors, adeno-associated virus, herpes simplex virus type 1, hybrid vectors. 
HERPES SIMPLEX VIRUS TYPE 1 - BIOLOGICAL 
PROPERTIES 
 Herpes simplex virus type 1 (HSV-1) is a member of the 
family Herpesviridae, subfamily Alphaherpesvirinae, genus 
Simplexvirus. It is a common human pathogen that causes 
infections of the orofacial mucosal surfaces and may rarely 
cause acute hepatitis, kerato-conjunctivitis or meningo-
encephalitis. 
 The HSV-1 particle is composed of three different 
compartments, capsid, tegument, and envelope. The capsid 
proteins are involved in the formation and maturation of the 
icosahedral capsid [1]  and packaging of the viral genome [2-
6]. The tegument, which is located between capsid and 
envelope, is composed of viral proteins involved in transport 
of capsids to nuclear pores, attachment to the nuclear pore 
complex [7], release of the virus genome from the capsid 
into the nucleus [8], and remodeling the host cell 
environment to optimize replication [9-14]. The viral 
envelope is a lipid bilayer of host origin that contains 11 
viral glycoproteins. These play important roles in viral 
attachment, entry, cell to cell spread, and egress [15, 16]. 
HSV-1 can enter the cells by receptor-mediated fusion 
between virus and cell membrane [17-20]. However, 
depending on the cell type and virus strain, HSV-1 can 
penetrate the host cell also by endocytosis [20-22]  and 
phagocytosis [23]. In the cytoplasm, the capsid is transported 
to the nucleus via interactions with the minus-end-directed 
microtubule motor protein dynein [24-26]  Capsids bind to 
the nuclear pore complex and release the DNA genome into 
the nucleus [7, 27, 28]. 
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 The HSV-1 genome is a double-stranded DNA (dsDNA) 
of 152 kbp. It is organized in two segments, unique long 
(UL) and unique short (US), both of which are flanked by 
inverted repeats (see Fig. 1). The essential cis elements for 
viral DNA replication and encapsidation include the origins 
of DNA replication, located in the UL (oriL) and TRs, (oriS) 
regions [29, 30], and the packaging/cleavage signals (pac) 
that reside in the a sequences located at both termini of the 
genome as well as at the junction between the long and the 
short segments [31]. The viral genome circularizes after it 
reaches the nucleus [32] and serves as a template for DNA 
replication. However, there is also evidence that 
circularization is not required for replication [33]. The 
majority of the replicative intermediates are long 
concatemers that are thought to have been synthesized by a 
rolling-circle mechanism [34-36]. The concatemers are 
cleaved into unit-length genomes at the pac signals after 
filling pre-formed capsids [36, 37]. 
 HSV-1 encodes approximately 89 genes [38], which are 
expressed in a cascade of three temporal phases: immediate-
early, early, and late. The late genes can be subdivided in 
leaky-late (expression is not dependent on viral DNA 
synthesis) and true-late (expression depends on viral DNA 
synthesis) [31, 39, 40]. 
 There are several hypotheses on the mechanisms of 
envelopment of the nucleocapsid. The generally accepted 
view suggests a two-step envelopment process in which the 
capsid acquires a primary envelope by budding at the inner 
nuclear membrane and then is de-enveloped by fusion with 
the outer nuclear membrane [41, 42]. The secondary 
envelope is acquired when the capsid buds into the Golgi or 
cytoplasmic vesicles [43-49]. The alternative pathways 
described include (i) budding at the inner nuclear membrane 
followed by intraluminal transport via ER and Golgi and (ii) 
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exit via impaired nuclear pores and envelopment at the outer 
nuclear membrane or ER membrane [50-52]. Regardless of 
the mechanism of envelopment, mature virions seem to exit 
the cell by exocytosis via intraluminal transport to Golgi 
cisternae and formation of transport vacuoles [53-55]. 
An important aspect of HSV-1 biology is the capability of 
this virus to establish latent infections in sensory neurons of 
the trigeminal ganglia [56]. The latent HSV-1 genome is a 
circular, condensed episome, and viral gene expression is 
limited to the non-coding, latency-associated transcripts 
(LATs) [57]. Expression of LATs was demonstrated to 
increase the number of neurons in which latency is 
established [58] and to affect the efficiency of reactivation 
[59, 60]. Recent findings that LAT encodes several micro 
RNAs (miRNA) in HSV-1 infected cells corroborates with 
the proposed hypothesis that the exonic regions of LAT 
might function as primary miRNA precursors [61]. At least 
two of the identified miRNA precursors in latently infected 
neurons may facilitate the establishment and maintenance of 
viral latency by post-transcriptionally regulating viral gene 
expression [62-65]. 
 Latent HSV-1 can periodically reactivate in response to a 
variety of stimuli, including fever, UV light, hormonal 
imbalance, malignancy or immune suppression, and enter a 
new lytic cycle, usually at the site of the primary infection. 
Recently, the requirement of ICP0 for viral DNA replication 
[66-68]  and for exit from latency has been reconsidered, as 
in vivo studies showed that reactivation of HSV-1 genomes 
does not depend on viral DNA amplification [69]  nor 
functional ICP0 [70]. Upon stress conditions, and in the 
absence of other viral proteins, VP16 was demonstrated to be 
activated [71], supporting the hypothesis that de novo 
expression of VP16 regulates entry into the lytic program in 
neurons. Repeated reactivation does not appear to kill the 
neurons, indicating that the extent of virus replication must 
be limited. 
 The understanding of the biological properties of HSV-1 
and the molecular mechanisms of virus replication have 
allowed the design of specialized vector systems for somatic 
gene therapy, oncolytic virotherapy, and vaccination. 
HSV-1 BASED VECTOR SYSTEMS 
 HSV-1 is an attractive vector for gene therapy due to its 
(i) large transgene capacity, (ii) high transduction efficiency 
and broad cell tropism that includes both dividing and non-
dividing cells, and (iii) ability to establish latency while 
maintaining at least some transcriptional activity. However, 
as HSV-1 is a human pathogen, its use as a vector can result 
in host immune responses and cytopathogenic effects in 
patients, and possibly reactivation of and recombination with 
latent wild-type HSV-1. Taking these aspects into 
consideration, two different HSV-1-based vector systems, 
recombinant and amplicon, have been developed. 
 Initially, recombinant herpesviruses were constructed for 
functional studies of viral genes and development of 
vaccines. However, advances in site-specific modification of 
the viral genome facilitated the use of HSV-1 as a gene 
transfer vehicle [72]. Different approaches for the 
construction of recombinant HSV-1 vectors are based on the 
target tissue and purpose of gene delivery e.g. replication-
conditional recombinant HSV-1 vectors are suitable for 
therapeutic treatment of tumors; replication-defective 
recombinant HSV-1 vectors are applied for gene replacement 
therapy [73]. Although some preclinical studies show 
promising results, several obstacles have to be overcome: (i) 
replication-defective mutants of HSV-1 can cause cytopathic 
effects in primary cultures of neuronal cells and 
inflammatory responses in neural tissue in vivo; (ii) most 
viral and nonviral promoters are silenced after injection into 
the brain. Therefore, the main focus in the development of 
new HSV-1-based vectors has been directed at achieving 
nontoxic, long-term gene expression in neurons. 
 The second type of HSV-1-based vector system, the 
HSV-1 amplicon vector, originated about three decades ago. 
Spaete and Frenkel analyzed the nature of defective virus 
genomes generated during the passage of standard HSV-1 
stocks at high multiplicity of infection [74, 75]. Their 
investigations revealed that an ori and a pac signal were the 
only two cis-acting sequences required for the replication 
and packaging of defective virus genomes in the presence of 
trans-acting HSV-1 helpervirus (Fig. 2A). The word 
amplicon was used to delineate the fact that multiple copies 
of a DNA sequence of interest can be amplified in a head-to-
tail arrangement in concatemeric defective virus genomes 
and packaged into HSV virions [76]. HSV-1 amplicon 
vectors share similar structural and immunological properties 
with the wild type HSV-1 particle, which can trigger cell 
signaling and cellular responses that may have a transient 
impact on cell homeostasis or gene expression. However, the 
lack of virus genes and protein synthesis reduces the risk of 
reactivation, complementation and recombination with latent 
or resident HSV-1 genomes. 
 HSV-1 amplicon vectors have been used to infect 
efficiently a number of different cell types, including 
 
Fig. (1). Schematic representation of the HSV-1 genome. The HSV-1 genome is a linear double stranded DNA of approximately 152 kb in 
size, composed of two unique segments, UL and US, which are flanked by inverted repeats, TRL /IRL and IRS/TRS. The minimal cis elements 
required for HSV-1 DNA replication and packaging include the origin of DNA replication, ori, and the cleavage/packaging, pac, signals. 
oriL oriSoriSpac pacpac
UL IRL USIRSTRL TRS
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epidermal cells and dendritic cells in the skin [77, 78], some 
cell types in the cochlea [79, 80], hepatocytes [81], skeletal 
muscle [82], neurons [83], glioblastoma, and other tumor 
cells [84-86]. Despite the promising features of the HSV-1 
amplicon vector as a gene delivery system, further 
developments concerning vector production, stability of 
transgene expression, and interaction with target cells are 
essential. Recently, the presence of bacterial sequences in the 
amplicon genome was shown to be responsible for the 
formation of inactive chromatin, leading to a rapid transgene 
silencing [87]. Strategies to increase the stability of 
transgene expression included the use of: (i) cell type-
specific promoters [88, 89]  and (ii) genetic elements from 
other viruses that confer genetic stability, such as integration 
of the transgene into host chromosomes [90, 91]  or 
conversion of the amplicon genome into a replication-
competent extrachromosomal element [92-95]. 
 One of these strategies, the combination of genetic 
elements from HSV-1 amplicons and adeno-associated virus 
(AAV) to achieve site-specific integration of the transgene 
into the host genome and long-term transgene expression is 
described in detail below, after a short introduction into 
AAV biology. 
ADENO-ASSOCIATED VIRUS – BIOLOGICAL PROP- 
ERTIES 
 Adeno-associated virus (AAV) belongs to the genus 
Dependovirus within the subfamily Parvovirinae, family 
Parvoviridae [96]. Different AAV serotypes have been 
identified that can infect a broad range of species; about 11 
serotypes and more than 100 variants of AAV infect 
primates. Based on serological studies, AAV serotypes 2, 3, 
and 5 most probably have a human origin [97, 98], while 
AAV4 appears to have originated in monkeys [99]. AAV6 
shares some genomic similarities with AAV2 and AAV1, 
raising the hypothesis that a recombination event could have 
occurred in vivo or in cell culture [100, 101]. The AAV 
serotypes 1 to 6 were isolated as contaminants in laboratory 
adenovirus stocks, while AAV 7, 8, 9, 10, and 11 were 
isolated as DNA molecules using a “signature PCR”, a 
 
Fig. (2). Viral vectors. A) HSV-1 amplicon. The HSV-1 amplicon contains three types of genetic elements: i) sequences from bacteria 
(colE1 and ampR) that allow plasmid propagation in E. coli; ii) sequences from HSV-1, in particular an origin of DNA replication (ori) and a 
DNA packaging/cleavage signal (pac), which allow replication and packaging of the amplicon DNA into HSV-1 particles in the presence of 
HSV-1 helper functions in mammalian cells; and iii) a transgene cassette with the gene of interest. B) Recombinant AAV vector. 
Recombinant AAV vectors are bacterial plasmids that contain the AAV ITRs flanking a transgene of interest. Replication of the ITR cassette 
and packaging into AAV particles is achieved by supplying helpervirus functions and the rep and cap genes in cis or trans but outside the 
ITR cassette. C) HSV/AAV hybrid amplicon. In addition to the HSV-1 amplicon elements, HSV/AAV hybrid amplicon vectors contain the 
AAV rep gene and a transgene of interest flanked by AAV ITRs. D) HSV/EBV hybrid amplicon. In addition to the HSV-1 amplicon 
elements, HSV/EBV hybrid amplicon vectors contain the EBV origin of DNA replication (oriP) and the gene encoding EBNA-1 which 
together can support episomal retention and segregation of the vector in dividing cells. E) HSV/RV hybrid amplicon. In addition to the 
HSV-1 amplicon elements, HSV/RV hybrid amplicon vectors contain the retrovirus (MoMLV) gag, pol, and env genes, and the RV LTRs 
flanking a transgene of interest. 
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screening-based strategy [102]. Despite being widespread 
among species and infecting different tissues, AAV 
infections have not been associated with any pathology. 
Primate AAV serotypes share significant sequence 
similarities, and the occurrence of cross-reaction of 
neutralizing antibodies may be species specific or depend on 
tissue type or route of administration [101, 103, 104]. 
 The genome of AAV is a linear single stranded DNA of 
4.7 kb, and either the positive or negative strand can be 
packaged with equal efficiency. The genome is flanked by 
inverted terminal repeats (ITR) of 145 bp, containing a 
palindromic sequence that forms a hairpin as a T-shaped 
secondary structure. The Rep binding site (RBS) and the 
terminal resolution site (TRS) are regions within the ITRs 
that play important roles in the replication and packaging of 
the AAV genome [105]  (Fig. 3A). Two open reading frames 
(ORFs), Rep and Cap, are responsible for encoding 
overlapping proteins through alternative splicing (Fig. 3B). 
The Rep proteins, Rep78/68, and Rep52/40 are transcribed 
from two different promoters, p5 and p19, respectively, and 
are involved in DNA replication, transcription, and 
chromosomal integration. The p5 promoter contains a TATA 
box, a RBS, a TRS, the Yin Yang 1 (YY1) binding site, and 
a downstream sequence that can form a hairpin structure. 
The RBS is involved in Rep-mediated promoter regulation 
activity [106, 107], thus in the absence of helper functions 
small amounts of Rep are expressed that bind to the p5 
promoter inhibiting transcription [108, 109]. The regulatory 
activity of Rep seems to be involved in the maintenance of a 
constant ratio of Rep and Cap proteins during infection in 
order to keep the balance between AAV genome replication 
and packaging. The Cap ORF encodes three overlapping 
proteins, VP1, VP2 and VP3, from a single promoter, p40. 
These structural proteins compose the AAV icosahedral 
capsid whose diameter ranges from 18 to 26 nm [110]. 
 
Fig. (3). Schematic map of the wild type AAV genome. A) 
Secondary structure formed by the inverted terminal repeat, ITR. 
Depicted are the Rep binding sites, RBEs, and the terminal 
resolution site, TRS. B) The AAV genome expresses two clusters 
of genes, rep and cap, from three different promoters, p5, p19, p40, 
by alternative splicing. 
 The replication of the AAV genome is based on a 
“rolling hairpin model”. The hairpin structure at the ITR acts 
as a primer that converts the DNA into a double-stranded 
template, and together with the essential cis-acting elements 
RBS and TRS, and helpervirus functions, the replication and 
transcription of the AAV genome is initiated [111-113]. The 
Rep78/68 proteins play major roles in the replication process 
due to DNA-binding, endonuclease, and helicase activities. 
After binding to the RBS, Rep induces a site- and strand-
specific nick at the TRS, creating a new genome end 
allowing the reinitiation of the synthesis and formation of a 
monomer extended form that can be packaged [114]. If the 
hairpin structure in the monomer turnaround form is not 
resolved before reinitiation on the other genome end, 
continued synthesis leads to double stranded dimer 
molecules, in which two genomes in the inverted 
orientations (head-to-head or tail-to-tail) are covalently 
joined by a single ITR [115]. Interestingly, the RBS and TRS 
signals located within the p5 promoter sequence have been 
demonstrated to act together as an alternative origin of DNA 
replication in the presence of adenovirus [116, 117]  or 
HSV-1 helpervirus functions [108]. Replication from a 
plasmid cloned p5 replication origin led to the accumulation 
of large, head-to-tail linked concatameric replication 
products, which could readily be packaged into HSV-1 
virions if the HSV-1 packaging/cleavage signal was included 
on the plasmid [108]. These findings indicate that the AAV 
p5 replication origin could substitute for the HSV-1 origin of 
DNA replication on HSV/AAV hybrid vectors (see below). 
AAV is a replication defective virus as it depends on a 
helper virus, such as adenoviruses [118], a herpesvirus [119-
121], or vaccinia virus [122]  for productive replication (Fig. 
4). Helper viruses are also responsible for inducing a cell 
cycle arrest in late S or G2 phase, as in the case of 
adenoviruses [123]  or for down regulating host cell 
functions as in the case of HSV-1 as the helpervirus [124, 
125]. 
 Many studies have assessed the different elements from 
the helperviruses required for AAV replication. A model has 
been proposed where the HSV-1 helicase/primase proteins 
constitute a scaffold that recruits ICP8, Rep and cellular 
replication (RPA) proteins to the self-primed AAV DNA 
into replication compartments [126-129]. The HSV-1 
polymerase complex is preferentially used for AAV 
replication instead of the cellular machinery [113, 130]. 
Interestingly, an inhibitory effect of Rep78/68 proteins has 
been described on HSV-1 replication [131, 132], suggesting 
a regulatory effect of AAV over HSV-1, thereby limiting 
expression of HSV-1 early genes [113, 129]. 
 In the absence of helpervirus, the AAV genome can 
integrate into a specific site termed AAVS1, on chromosome 
19q13.3-qter of human cells [133-136]  (Fig. 4). The 
integration is mediated by Rep78/68 and ITRs through a 
nonhomologous deletion/insertion recombination event [134, 
136-143]. Also, an integration efficiency element (IEE) has 
been identified within the p5 promoter of AAV [144], and 
more specifically a 16-bp RBE was shown to be sufficient 
for AAV genome integration [145]. Rescue of the integrated 
AAV genome is possible by superinfection with helper virus 
[130]. Although HSV-1 ICP0 seems to contribute to the 
activation of the rep gene from latent AAV genomes [146],  
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Fig. (4). The life cycle of AAV. Co-infection of AAV and 
helpervirus, adenovirus or HSV-1, leads to viral gene expression, 
viral DNA replication, and production of progeny virus. In the 
absence of helpervirus, the genome of AAV can integrate into a 
specific site on human chromosome 19. In the presence of 
helpervirus, integrated AAV genomes are rescued and enter the 
lytic replication cycle. 
it is not sufficient to induce rep synthesis [130]. Some 
studies have demonstrated the autonomous replication of 
AAV under special conditions [147-149], however, the 
efficiency of replication is significantly lower than in 
presence of helpervirus functions. 
 AAV can infect different tissues and bind to unique 
cellular receptors, which can account for a serotype-specific 
tissue tropism. Several cellular receptors used by AAV for 
cell entry have been identified, including heparan sulfate 
[150], fibroblast growth factor receptor [151], and integrin 
alphaVbeta5 [152]. The initial steps of AAV infection, 
attachment to cellular glycosaminoglycan receptors and 
interactions with coreceptors seem to define the intracellular 
trafficking pathway of the capsid. Upon entry, AAV capsids 
are endocytosed via clathrin-coated pits [153], a process that 
requires dynamitin [154], and transported through both late 
and recycling endosomes. Trafficking in recycling 
endosomes appears to be favorable for efficient transgene 
expression [155]. The process of uncoating is still not well 
characterized [153, 156], however, AAV appears to enter the 
nucleus through a mechanism independent of the nuclear 
pore complex [157]. 
AAV BASED VECTORS 
 The broad cell tropism, lack of pathogenicity, and stable 
long-term gene expression make AAV an attractive vector 
for gene therapy [158]. AAV2 was the first AAV isolate to 
be developed into a recombinant vector for transgene 
delivery as it has been shown to infect a broad range of cell 
types in animal models [159], showing high efficiency in 
most of the tumor cells tested [160]. Recombinant AAV 
vectors are constructed by replacing the Rep and Cap ORFs 
with a transgene of interest flanked by the ITRs. Rep, Cap 
and helper functions can be supplied in trans in order to 
allow replication of the transgene in the host cell [135]  (Fig. 
2B). Different methods of delivering helper functions have 
evolved, from co-infection with Ad or HSV-1 [161, 162], to 
plasmid-based protocols [163], and stable-expression by cell 
lines [164-166]. The development of a baculovirus based 
vector production method in insect (SF9) cells has also 
shown promising results [167, 168]. 
 Recombinant AAV vectors have been tested in 
preclinical studies for a variety of diseases such as 
hemophilia, -1 anti-trypsin deficiency, cystic fibrosis, 
Duchenne muscular dystrophy, rheumatoid arthritis, prostate 
and melanoma cancer, Canavan disease [169], Alzheimer’s, 
and Parkinson’s [170]. 
 Recombinant AAV have shown efficient transduction of 
different regions of the brain, and are currently used in several 
clinical trials for neurological disorders [171-173]. Increased 
interest in designing AAV vectors for the treatment of 
neurodegenerative diseases that require gene delivery to broad 
areas or very local and specific areas of the brain are now the 
focus of many studies [174]. AAV2 has been the most widely 
used AAV serotype for gene delivery to the CNS, transducing 
almost exclusively neurons in different brain structures [175-
178], and supporting long-term transgene expression in the CNS 
[179-181]  as well as in the dorsal root ganglia [182]. AAV2 has 
shown higher transduction efficiency in glioblastoma in vitro 
and in vivo when compared to serotypes 4 and 5 [183]. 
However, other studies have demonstrated a higher distribution 
and transduction in the CNS when using rAAV serotypes 1 and 
5 [175, 184, 185]. The different AAV serotypes have been 
exploited on their ability to efficiently transduce distinct regions 
of the brain due to different cellular tropisms [174, 183, 186]. 
Immune Response to rAAV Vectors 
 The brain has been thought to be an immune privileged, 
compartmentalized organ that lacks an adaptive immune 
response. Some studies have suggested that viral vectors 
induce little immunogenicity, especially when injected once 
in the parenchyma of naïve animals [104, 187, 188], or that 
the presence of antibodies to both capsid proteins and 
transgene products seems not to correlate with reduction in 
transgene expression [187, 188]. Further studies with pre-
immunized animals, however, established that circulating 
neutralizing antibodies can affect intracerebral rAAV-
mediated transduction, and even suggested that the adaptive 
arm of the immune system can be primed by intracerebral 
rAAV2 administration [104]. 
 Immune responses in the absence of expression of AAV 
genes have also been observed in naïve animals in a dose-
dependent manner [104]. This has been suggested to occur 
due to the slow process of AAV capsid uncoating, thus 
allowing antigen presentation of processed capsid peptides 
by MHC-I, or by an immune reaction specific to the 
transgene [189, 190]. 
Improvements on rAAV Vectors 
 Despite the explicit advantages of rAAV as a vector for 
gene therapy, improvements in the regulation of transgene 
expression need to be achieved in order to confer safety. 
– helpervirus+ helpervirus
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Much research is focused on efforts to limit vector spread, in 
order to achieve specific tissue or organ delivery, or to 
enable the transduction of tissues that are refractory to 
naturally occurring AAV vectors. Engineering of AAV 
vectors for altered tropism, enhanced transduction efficiency, 
and evasion of antibody neutralization includes manipulation 
of the AAV capsid by insertion of peptide ligands, 
conjugate-based targeting, and presentation of large protein 
ligands on the AAV capsid [191]. The diversity of AAV 
serotypes brings the possibility to evade preexisting 
immunity by engineering hybrid or pseudotyped AAV 
vectors derived from different serotypes [192-194]. 
 Another strategy that focuses on the transduction 
efficiency is the improvement on the second-strand synthesis 
step during AAV replication (Fig. 5). The development of 
self-complementary AAV (scAAV) vectors relies on the 
packaging of an inverted repeat genome that can fold into 
dsDNA without the requirement for DNA synthesis or base-
pairing between multiple vector genomes, thereby bypassing 
the rate-limiting second-strand DNA synthesis [195]. The 
scAAV vectors displayed enhanced transduction in 
comparison with conventional AAV vectors in some tissues 
and cancer cells but their efficiency still depends on tissue, 
cell type, and route of administration [196, 197]. 
 
Fig. (5). Comparison between self-complementary AAV 
(scAAV) and rAAV vectors. scAAV delivers a dimeric inverted 
repeated DNA molecule thereby bypassing the rate-limiting second-
strand DNA synthesis of rAAV. 
 Modifications on purification protocols using 
chromatography techniques have also contributed to 
increased yields of rAAV and to considerable elimination of 
contaminating infectious helper viruses [198-201]. 
 
HSV/AAV HYBRID VECTORS 
Rationale on the Construction of Hybrid Vectors 
 Hybrid gene transfer vectors are designed to combine 
advantageous properties of different viruses to enhance 
efficiency of transgene delivery, vector stability and long-
term transgene expression, while maintaining high safety 
standards [133, 202]. For example, the instability of HSV-1 
amplicon vector delivered transgene DNA and transient 
transgene expression can be overcome by introducing 
genetic elements that allow the amplicon DNA to be 
maintained as an episome or to integrate into the host cell 
genome [203]. The maintenance of the DNA as a replicating 
episome with chromosome-segregating capability can be 
achieved by using oriP and the EBNA-1 gene from Epstein-
Barr virus (EBV) [204]. Alternatively, viral elements such as 
AAV ITR and rep [91, 178], or retrovirus components [205]  
can be used to allow HSV-1 amplicon vector delivered 
transgenes to integrate into the cell genome. HSV-1 based 
hybrid vectors have also been constructed to facilitate the 
production of rAAV vectors. 
Hybrid Vectors for the Production of rAAV Vectors 
 The efficiency of rAAV production for routine clinical 
use is a major concern, as most of the systems used for 
rAAV production rely on transfection protocols, thereby 
limiting scale-up procedures [206-209]. Replication 
defective rHSV-1 vectors lacking specific genes (e.g. ICP4, 
ICP27), which have been developed in order to reduce 
pathogenicity and cytotoxic effects in vector infected cells, 
can also be used as helper viruses for the production of 
rAAV vectors. Specifically, the ability of rHSV-1 that lack 
the ICP27 gene to efficiently act as a helper virus for rAAV 
production has been demonstrated [210] ; rAAV production 
in the absence of ICP27 appeared to be even enhanced. This 
may be due to the role of ICP27 in regulating transcription 
and translation of viral and cellular genes, for instance in the 
inhibition of splicing of host and AAV transcripts, which 
reduces synthesis of Rep and Cap proteins. The use of 
replication defective rHSV-1 to deliver AAV rep and cap 
has also been explored and is a very promising approach as it 
generates higher yields of rAAV with no detectable 
helpervirus contamination. Moreover, when allied to 
infection of a cell line that provides the rAAV template to be 
packaged, transfection steps can be avoided entirely for the 
production of rAAV [161, 211]. A protocol with a single 
infection step can also be accomplished by inserting an AAV 
ITR-flanked transgene (rAAV genome) cassette into the 
genome of the rHSV-1 helpervirus [210]. 
HSV/AAV Hybrid Vectors for Site-Specific Integration 
into AAVS1 
 Over the past 2 decades, the development of improved 
HSV-1 amplicon packaging systems, in particular the 
development of helper virus-free packaging systems, has 
greatly reduced toxicity and immunogenicity, but has had 
little effect on the stability of amplicon-mediated transgene 
expression [81, 212-214]. On the other hand, classical rAAV 
vectors have a small transgene capacity (~4.6 kb) and, due to 
the replacement of the rep and cap genes by transgenic 
sequences, do not conserve the potential of the parent virus 
for site-specific integration. 
scAAVrAAV
gene 
expression
nucleus
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 HSV/AAV hybrid amplicon vectors have been developed 
to overcome these limitations. In addition to the standard 
HSV-1 amplicon elements, HSV/AAV hybrid vectors 
incorporate the AAV rep gene and a transgene cassette that 
is flanked by AAV ITRs (Fig. 2C). By placing the rep gene 
outside of the ITR cassette, it is not expected to integrate into 
the host genome. Loss of rep after integration of the ITR 
cassette eliminates a potential source of toxicity and the risk 
of rescue/excision of integrated ITR cassettes if the cell is 
infected by a helpervirus. Because HSV/AAV hybrid vectors 
can be packaged into HSV-1 virions, they conserve the high 
efficiency of gene transfer, the large transgene capacity, and 
the availability of helper virus-free packaging systems. 
However, after delivery into the host cell nucleus, the vector 
has the potential to act like AAV with rep-mediated site-
specific integration of the ITR-flanked transgene cassette 
into the AAVS1 sequence of human chromosome 19 [91]. 
 The initial study on HSV/AAV hybrid vectors 
demonstrated that these vectors can be packaged into HSV-1 
virions by using either helper virus-dependent or helper 
virus-free packaging systems [81, 215]. Hybrid vectors 
supported transgene retention and expression significantly 
longer than standard amplicons [215]. Although the 
possibility of transgene integration had not been specifically 
addressed in that study, the percentage of cells expressing 
the transgene was consistently higher with hybrid vectors 
that contained the rep gene than with those without rep, or 
with standard amplicons. 
 Two other studies have specifically addressed the 
question whether HSV/AAV hybrid vectors mediate 
genomic integration, both randomly or site-specifically at the 
AAVS1 site on human chromosome 19 [91, 178]. Heister 
and colleagues constructed HSV/AAV hybrid vectors that 
contained enhanced green fluorescent protein (EGFP) 
reporter gene flanked by the AAV ITRs and AAV rep. 
Replication assays demonstrated that both the AAV elements 
and the HSV-1 elements were functional in the context of the 
hybrid vector, as shown by the presence of replication 
intermediates of the ITR-flanked transgene cassette and high 
molecular-weight concatemeric products of replication from 
the HSV-1 origin of DNA replication. Such hybrid vectors 
could be packaged into HSV-1 virions, although the rep 
sequences incurred a drastic (20 to 2,000-fold) reduction in 
titers. Site-specific integration at AAVS1 was directly 
demonstrated by PCR and sequence analysis of ITR-AAVS1 
junctions in transduced human 293 cells. The junctions were 
similar to those that had been identified in cells infected with 
wt AAV [133, 134, 138, 139, 216-218]. Similar results were 
obtained by Wang and colleagues who have used also 293 
cells and extended the study to other cell lines, including 
glioma cells (gli36) and primary myoblasts [178]. These 
investigators used HSV/AAV hybrid vectors that contained 
rep68 and rep78, or no rep, and an ITR-flanked transgene 
cassette that consisted of an EGFP reporter gene and a 
neomycin resistance gene. In order to overcome the low-titer 
packaging problem inherent to the rep gene, they worked on 
position/orientation effects and found that a decent amplicon 
vector titer is achieved when the rep genes are placed 
downstream of the ITR cassette in the forward orientation. 
Rep mediated a significantly improved efficiency of stable 
tranduction in all human cells tested, including 293 cells, 
glioma cells and primary myoblasts. Although neomycin 
selection was employed for cell cloning, a high proportion of 
the stably transduced cells had the transgene sequences 
correctly integrated at the AAVS1 site. In summary, 
inserting the AAV ITRs and rep genes into an HSV-1 
amplicon considerably improved the frequency of stable 
transgene expression in various proliferating human cell 
types. Integration events of 4-5 kb ITR-flanked transgene 
cassettes occurred at a rate of approximately 10-30 % of the 
HSV/AAV hybrid vector infected cells, and about 50% of 
those events occurred specifically at the AAVS1 locus [91, 
178]. The potential for AAVS1-specific integration and 
expression of an entire gene under control of its endogenous 
promoter using the HSV/AAV vector has also been 
evaluated. Large functional inserts (approximately 100 kb) 
could be integrated at the AAVS1 site but with a reduced 
efficiency [219, 220]. 
 While the expression of rep78/68 has been demonstrated 
to be essential for the ability of HSV/AAV hybrid vectors to 
mediate site-specific integration, Rep proteins have a strong 
inhibitory effect on the HSV-1 replication machinery [91, 
132, 178, 221]. As a consequence, the titers of HSV/AAV 
hybrid vectors are up to 2000-fold lower than those of 
standard amplicon vectors [91]. This could be due to (i) the 
toxicity of Rep, resulting in compromised cell metabolism 
[222], (ii) the ability of Rep to inhibit HSV-1 replication 
[131, 132], or (iii) the excision of ITR-flanked sequences 
from the amplicon DNA during packaging. 
 Potential improvements of the HSV/AAV amplicon 
vectors may rely on the appropriate use of the p5 promoter 
sequence. Indeed, the p5 promoter driving the expression of 
rep78/68 in the afore described HSV/AAV hybrid vectors 
[91, 178]  may promote vector-backbone integration [144, 
223]  owing to its location outside of the therapeutic 
transgene cassette. In addition, it may also interfere with 
site-specific integration of the p5-free ITR-flanked 
transgenes. Transferring the p5 promoter sequence from the 
rep expression cassette to the transgene cassette may not 
only solve the problem of inadvertent integration of vector 
backbone sequences but also increase the efficiency of site-
specific integration of the ITR cassette [144, 223]. 
 Liu et al. developed a strategy to overcome the negative 
effect of AAV Rep on hybrid vector replication and 
packaging [224]. These investigators designed an HSV/AAV 
hybrid vector in such a way that little or no rep was 
expressed during packaging. However, rep was expressed in 
transduced cells if Cre-recombinase was provided; following 
site-specific integration, rep was suppressed again. These 
vectors mediated stable expression in 22% of transduced 
Cre-expressing 293 cells. Of those cells, approximately 70% 
transduction efficiency was achieved by Rep-mediated site-
specific integration. 
 The finding that concatameric plasmid replication 
products from the AAV p5 replication origin can be 
packaged into HSV-1 virions if HSV-1 pac is included on 
the plasmid [108]  could lead to the construction of a novel 
generation of HSV/AAV hybrid amplicon vectors which 
replicate from a heterologous origin of DNA replication. 
Such a vector system would have several advantages: first, 
as described by Philpott and coworkers, the AAV p5 element 
can efficiently mediate site-specific vector integration into 
AAVS1 on human chromosome 19 and support long term 
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transgene expression [144, 225]. Second, the AAV p5 
replication origin is not inhibited by rep expression, but 
instead depends on the presence of AAV Rep protein in the 
replication/packaging process [108, 116, 117]. 
 The HSV-1 virion contains three proteinaceous 
compartments for delivery - envelope, tegument, and capsid 
– which could all be used to deliver functional foreign 
proteins by fusion with virion components [226]. For 
example, AAV Rep could be fused with VP16, an abundant 
HSV-1 tegument protein that enters the cell nucleus along 
with the virus genome. This would allow eliminating the rep 
gene from the HSV/AAV hybrid vector genome, as Rep 
protein could enter the cell nucleus as a fusion with VP16 
and there may mediate efficient site-specific integration of 
the transgene sequences via p5 or ITRs. 
 The full potential of HSV/AAV hybrid vectors still needs 
to be evaluated for site-specific integration in vivo, for 
example in transgenic mice that carry the human-specific 
AAVS1 genomic element [227]. As murine [228]  and 
simian [229]  AAVS1 orthologs have been found, AAV2 
likely can mediate site-specific integration in other species as 
well. 
 Future perspective and clinical use of HSV/AAV hybrid 
vectors are closely linked to standard HSV-1 amplicon 
vectors as both vector systems depend on the same 
packaging procedure. Helper virus-free packaging systems 
require transient transfection of vector DNA and packaging-
defective HSV-1 helper DNA, which limits scale up 
potential. The use of amplicon vectors for clinical trials 
depends, therefore, on the design of novel packaging 
procedures that allow the production of large amounts of 
vector stocks with high titers. Strategies to overcome the 
adverse effects of the AAV rep gene on the titers of 
HSV/AAV hybrid vectors have been discussed above. The 
presence of the genetic elements from AAV on HSV-1 
amplicon vectors should not add additional safety concerns 
to the amplicon system, as AAV is not known to be 
pathogenic in humans and AAV vectors are already being 
used in clinical trials. 
OTHER HYBRID AMPLICON VECTORS 
HSV/EBV Hybrid Vectors 
 Epstein-Barr virus, a human Gammaherpesvirus, has also 
been used as a hybrid partner with HSV-1 amplicons, due to 
its potential to persist as an extrachromosomal element in B-
lymphocytes [230]. The EBV nuclear antigen (EBNA-1) and 
the origin of DNA replication (oriP) are the sole elements 
necessary for the long-term episomal retention and are 
therefore incorporated into the HSV-1 amplicon backbone to 
support replication and mitotic segregation of the amplicon 
concatenate in the host cell nucleus [231, 232]  (Fig. 2D). 
HSV/EBV hybrid amplicon vectors have been demonstrated 
to efficiently transduce various human cells in culture and to 
support retention of vector sequences in dividing human 
cells [205]. Stable expression from large transgenes has also 
been demonstrated [233, 234]. Maintenance of transgene 
DNA in an episomal state as opposed to genomic integration 
reduces adverse effects in the host cell. However, long-term 
expression by these vectors depends on selective pressure 
and expression of EBNA-1 [95, 235]. In order to circumvent 
the potential immunogenic and oncogenic properties of 
EBNA-1 [236], the use of a human episomal retention 
element (scaffold/matrix attachment region (S/MAR) from 
the human -interferon gene to generate a novel HSV-1 
amplicon-based episomal vector has shown great potential 
even in the absence of selection pressure [93]. 
HSV/RV Hybrid Vectors 
 Elements from retroviruses (RV) have been combined 
with HSV-1 amplicons in order to achieve prolonged 
transduction of transgenes. Retroviruses, such as Moloney 
murine leukaemia virus (MoMLV), integrate randomly into 
the genome of dividing cells, and produce viral progeny 
without killing the host cell [237]. Due to the low efficiency 
of gene transfer, MoMLV –based vectors have been mostly 
used for ex vivo gene therapy protocols [238, 239]. Although 
this strategy has shown some therapeutic success in 
experimental brain tumors [240, 241]  it is not effective 
when used in human trials [242-245]. HSV/RV hybrid 
amplicon vectors containing genetic elements from MoMLV 
have been developed in order to transduce genes required for 
the de novo synthesis of small defective retrovirus vectors. 
These hybrid vectors contain the long terminal repeat 
sequences (LTRs) flanking a transgene cassette, and the gag, 
pol, and env genes in a separate cassette (Fig. 2E). The LTRs 
and psi sequence comprise the signals necessary for 
packaging of virion RNA, reverse transcription, and 
integration into host cell genome. HSV/MoMLV hybrid 
vectors have indeed been demonstrated to support the 
packaging of genomic retrovirus RNA expressed from the 
amplicon vector into MoMLV particles and accomplish 
integration and transgenic expression in infected naïve cells 
[246]. One point of caution, however, is the danger of 
endogenous retroviruses complementing retroviral elements 
in hybrid vectors. The possibility that endogenous integrases 
can act on LTRs in hybrid amplicon vectors has indeed been 
demonstrated [247]. In order to enhance the transduction 
efficiency of a therapeutic gene in vivo and increase its 
expression stability, hybrid vectors containing elements from 
more than 2 viruses have been developed as well. These 
tribid vectors are based on HSV-1 amplicon vectors and 
contain elements from MoMLV and either EBV or AAV 
[205, 248]. 
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